We translate frontier research on newly discovered drug targets, into preclinical therapeutics.
We are discovering and developing small molecule therapeutics that demonstrate target engagement and deliver lasting disease-modifying effects.
We focus on novel disease targets, with validated clinical relevance, that fit our discovery paradigm. This offers an unmatched promise of revolutionizing the standard of care.
We lead by merging cell and structure-based data with information-driven strategies, to build a cutting-edge drug discovery engine.
We harness advanced biostructural, biochemical, and biophysical technologies to design first-in-class therapeutics against clinically relevant drug targets.